Bio

She is currently associated with a number of global investor groups and is among the key decision makers for investments in a variety of areas including pharmaceuticals, biotech, medical devices/diagnostics, healthcare IT and genomics. Having studied endocrinology, Juliet started her career with Genentech. She then joined Baxter Healthcare and led the global regulatory approval for rFactor VIII, one of the first biotech products on the market. Juliet then joined Allergan and led the regulatory approval for Botox. Juliet was corporate officer with Collateral Therapeutics, acquired by Schering AG before becoming CEO/founder of a pharmaceutical company which she took public. Juliet has global access to investors, deal flow and serves on several boards.